Online inquiry

IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ752MR)

This product GTTS-WQ752MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, AAB-001(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ752MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4496MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BMS-931699
GTTS-WQ9591MR IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA JNJ-61610588
GTTS-WQ13470MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ4437MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-734016
GTTS-WQ1754MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ADCT-301
GTTS-WQ9008MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMA-638
GTTS-WQ8070MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA h2H12ec
GTTS-WQ1062MR IVTScrip™ mRNA-Anti-TNFRSF10B, ABBV-621(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-621
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW